CN107847490A - 改进的地拉罗司制剂及制备其的方法 - Google Patents

改进的地拉罗司制剂及制备其的方法 Download PDF

Info

Publication number
CN107847490A
CN107847490A CN201680042313.0A CN201680042313A CN107847490A CN 107847490 A CN107847490 A CN 107847490A CN 201680042313 A CN201680042313 A CN 201680042313A CN 107847490 A CN107847490 A CN 107847490A
Authority
CN
China
Prior art keywords
dfx
pharmaceutical composition
poly
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680042313.0A
Other languages
English (en)
Chinese (zh)
Inventor
达夫·A·米勒
贾斯廷·M·基恩
桑德拉·U·库塞拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diffusion technology co Ltd
Original Assignee
Diffusion technology co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diffusion technology co Ltd filed Critical Diffusion technology co Ltd
Publication of CN107847490A publication Critical patent/CN107847490A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680042313.0A 2015-06-17 2016-06-17 改进的地拉罗司制剂及制备其的方法 Pending CN107847490A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Publications (1)

Publication Number Publication Date
CN107847490A true CN107847490A (zh) 2018-03-27

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042313.0A Pending CN107847490A (zh) 2015-06-17 2016-06-17 改进的地拉罗司制剂及制备其的方法

Country Status (10)

Country Link
US (4) US10265301B2 (enExample)
EP (1) EP3310354A4 (enExample)
JP (1) JP2018517734A (enExample)
CN (1) CN107847490A (enExample)
AU (3) AU2016280280B2 (enExample)
CA (1) CA2989145C (enExample)
HK (1) HK1254608A1 (enExample)
IL (1) IL256322B (enExample)
MA (1) MA43271A (enExample)
WO (1) WO2016205658A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205A (zh) * 2022-05-30 2022-09-02 上海奥科达生物医药科技有限公司 地拉罗司颗粒剂中相关杂质的检测方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565279B1 (en) 2007-12-05 2014-12-03 Complete Genomics, Inc. Efficient base determination in sequencing reactions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN107267596A (zh) 2009-06-15 2017-10-20 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
WO2020061474A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20130142871A1 (en) * 2010-07-08 2013-06-06 Ratiopharm Gmbh Oral dosage form of deferasirox
CN103209687A (zh) * 2010-10-01 2013-07-17 希普拉有限公司 包含地拉罗司的药物组合物
US20130338356A1 (en) * 2010-08-25 2013-12-19 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-lH-l , 2, 4-triazolTl-yl] benzoic acid
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition
US20150017241A1 (en) * 2013-03-08 2015-01-15 Novartis Ag Oral formulations of deferasirox

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20130142871A1 (en) * 2010-07-08 2013-06-06 Ratiopharm Gmbh Oral dosage form of deferasirox
US20130338356A1 (en) * 2010-08-25 2013-12-19 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-lH-l , 2, 4-triazolTl-yl] benzoic acid
CN103209687A (zh) * 2010-10-01 2013-07-17 希普拉有限公司 包含地拉罗司的药物组合物
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
US20150017241A1 (en) * 2013-03-08 2015-01-15 Novartis Ag Oral formulations of deferasirox
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUY VAN DEN MOOTER: "The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate", 《DRUG DISCOVERY TODAY: TECHNOLOGIES》 *
HSIU-HAO CHANG ET AL.: "Improved Efficacy and Tolerability of Oral Deferasirox by Twice-Daily Dosing for Patients With Transfusion-Dependent b-Thalassemia", 《PEDIATR. BLOOD CANCER》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205A (zh) * 2022-05-30 2022-09-02 上海奥科达生物医药科技有限公司 地拉罗司颗粒剂中相关杂质的检测方法
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法

Also Published As

Publication number Publication date
US11878005B2 (en) 2024-01-23
MA43271A (fr) 2018-09-26
AU2016280280A1 (en) 2018-01-04
US20170027911A1 (en) 2017-02-02
AU2021277731A1 (en) 2021-12-23
CA2989145C (en) 2024-10-29
JP2018517734A (ja) 2018-07-05
US20190167643A1 (en) 2019-06-06
EP3310354A1 (en) 2018-04-25
US20170296514A1 (en) 2017-10-19
AU2024202528A1 (en) 2024-05-09
US20240091201A1 (en) 2024-03-21
AU2021277731B2 (en) 2024-04-11
CA2989145A1 (en) 2016-12-22
WO2016205658A1 (en) 2016-12-22
HK1254608A1 (zh) 2019-07-26
US10258608B2 (en) 2019-04-16
US10265301B2 (en) 2019-04-23
IL256322A (en) 2018-02-28
AU2016280280B2 (en) 2021-09-02
EP3310354A4 (en) 2018-12-12
IL256322B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US20240091201A1 (en) Formulations of deferasirox and methods of making the same
AU2017262586B2 (en) Improved drug formulations
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
EP1448168B1 (en) Pharmaceutical formulation comprising bicalutamide
US9555026B2 (en) Solid dispersion comprising amorphous cilostazol
JP7378393B2 (ja) 改善された薬物製剤
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
WO2003043630A1 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
HK40000762A (en) Improved drug formulations
HK1218618B (en) Solid dispersion comprising amorphous cilostazol
NZ623628A (en) Solid oral pharmaceutical formulations comprising amorphous (s)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1h-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (compound a)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180327

RJ01 Rejection of invention patent application after publication